Reversing T cell dysfunction in cancer by multimodal genetic screening

Project Information

ReverT

Grant agreement ID: 101054465

DOI

10.3030/101054465

EC signature date 8 June 2022

Start date 1 October 2022

End date 30 September 2027

Funded under

• European Research Council (ERC)

Total cost

€ 2 499 375,00

EU contribution

€ 2 499 375,00

Coordinated by

STICHTING HET NEDERLANDS KANKER INSTITUUT-ANTONI VAN LEEUWENHOEK ZIEKENHUIS
Netherlands

CORDIS provides links to public deliverables and publications of HORIZON projects.

Links to deliverables and publications from FP7 projects, as well as links to some specific result types such as dataset and software, are dynamically retrieved from OpenAIRE .

Publications

Peer reviewed articles (1)

Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness

Author(s): Lin, Chun Pu; Levy, Pierre L.; Alflen, Astrid; Apriamashvili, Georgi; Ligtenberg, Maarten A.; Vredevoogd, David W.; Bleijerveld, Onno B.; Alkan, Ferhat; Malka, Yuval; Hoekman, Liesbeth; Markovits, Ettai; George, Austin; Traets, Joleen J.H.; Krijgsman, Oscar; van Vliet, Alex; Poźniak, Joanna; Pulido-Vicuña, Carlos Ariel; de Bruijn, Beaunelle; van Hal-van Veen, Susan E.; Boshuizen, Julia; van der Helm, Pim W.; Díaz-Gómez, Judit; Warda, Hamdy; Behrens, Leonie M.; Mardesic, Paula; Dehni, Bilal; Visser, Nils L.; Marine, Jean Christophe; Markel, Gal; Faller, William J.; Altelaar, Maarten; Agami, Reuven; Besser, Michal J.; Peeper, Daniel S.
Published in: Cancer Cell, 2024, ISSN 1878-3686
Publisher: Cancer Cell
DOI: 10.1016/J.CCELL.2024.02.016